S'abonner

Population-based screening for hemochromatosis using phenotypic and DNA testing among employees of health maintenance organizations in Springfield, Missouri - 08/09/11

Doi : 10.1016/S0002-9343(99)00163-1 
Sharon M McDonnell, MD, MPH a, , Alexander Hover, MD b, Donna Gloe, RN b : EdD, Chin-Yih Ou, PhD c, Mary E Cogswell, DrPH a, Laurence Grummer-Strawn, PhD a
a Maternal and Child Nutrition Branch (SMM, MEC, LG-S), Division of Nutrition and Physical Activity, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA 
b St. John’s Health Regional Health System (AH, DG), Department of Quality Resources, Springfield, Missouri, USA 
c Molecular Biology Branch (C-YO), Division of Environmental Health Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA 

*Requests for reprints should be addressed to Sharon M. McDonnell, MD, MPH, CDC, Mail Stop C-08, 1600 Clifton Road, Atlanta, Georgia 30333

Abstract

BACKGROUND: Hemochromatosis reportedly affects 3 to 8 persons per 1,000 and is associated with an elevated risk of morbidity and mortality. We sought to ascertain its prevalence in a community and to assess the association between phenotype and genotype.

METHODS: All health maintenance organization employees were invited to participate in hemochromatosis screening using a repeated elevation of the transferrin saturation test as the case definition (≥50% in women and ≥60% in men with no other cause). Iron overload from hemochromatosis was defined as serum ferritin concentration ≥95th percentile and mobilizable iron ≥99th percentile for age and sex, or hepatic iron index ≥1.9. The HFE gene was analyzed for mutations.

RESULTS: Participation among employees was 28% (1,653 of 6,000); 83% were women. The prevalence of hemochromatosis was 8 per 1,000 (13 of 1,653), and the prevalence of iron overload from hemochromatosis was 4 per 1,000 (5 of 1,653). Compared with those who had no HFE mutation, the relative risk (RR) for hemochromatosis was greatest for C282Y homozygotes (RR = 147), compound heterozygotes (RR = 19), and H63D homozygotes (RR = 9). Overall, 38% of participants had at least one HFE mutation. Screening based on an initial elevated transferrin saturation test had the best sensitivity, whereas DNA testing offered the best specificity and predictive value positive for iron overload disease.

CONCLUSIONS: In this population, we found a greater than expected prevalence of hemochromatosis and demonstrated a clear association with the HFE genotype. Promotion of screening is complicated by controversies in case definition and the large number of persons who will be detected before they have clinically significant iron loading, in whom the risk of clinical disease is unknown. Larger screening studies in more diverse populations are necessary to characterize the burden of disease and to follow those at risk (based on HFE or iron status measures) to establish the natural history of hemochromatosis.

Le texte complet de cet article est disponible en PDF.

Plan


 Supported by the Centers for Disease Control and Prevention Grant number 1700.


© 1999  Excerpta Medica Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 107 - N° 1

P. 30-37 - juillet 1999 Retour au numéro
Article précédent Article précédent
  • Upper and lower gastrointestinal evaluation of elderly inpatients who are iron deficient
  • Etienne Joosten, Bart Ghesquiere, Hilde Linthoudt, Francis Krekelberghs, Eddy Dejaeger, Steven Boonen, Johan Flamaing, Walter Pelemans, Martin Hiele, Anne-Marie Gevers
| Article suivant Article suivant
  • Does a year make a difference? changes in physician satisfaction and perception in an increasingly capitated environment
  • Eric S Nadler, Suzanne Sims, Patrick H Tyrance, David G Fairchild, Troyen A Brennan, David W Bates

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.